Wall Street analysts have labeled seven biotech firms as potential takeover targets this year, as mentioned in GEN’s recent list, “Takeover Targets: Who Is First on the List?”. Of the seven, which do you think is the MOST likely target?

Poll Question:
Which company below do you think is the MOST likely to be acquired by a larger biotech partner or pharma giant?

Ariad Pharmaceuticals
30

Biomarin Pharmaceutical
33

Clovis Oncology
13

Incyte
29

Medivation
8

Regeneron Pharmaceuticals
34

Seattle Genetics
48

Previous articlePfizer Licenses Gliknik’s GL-2045 in $25M+ Deal
Next articlemyNaturalist